3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Sezary Syndrome
2
Recurrence
2
Neoplasms
2
Mycosis Fungoides
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Soft Tissue Neoplasms
1
Sarcoma
1
Respiratory Distress Syndrome
1
Radiation Pneumonitis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Interventions
Imatinib Mesylate
10
Sunitinib
4
spartalizumab
2
pembrolizumab
2
nilotinib
2
Surveys and Questionnaires
2
tanespimycin
1
ribociclib
1
pexidartinib
1
pazopanib
1
olaratumab
1
oblimersen
1
motexafin lutetium
1
masitinib
1
guadecitabine
1
ferric carboxymaltose
1
famitinib
1
epacadostat
1
Surgical Procedures, Operative
1
Quality of Life
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Immunoglobulin G
1
Fluorescein
1
Disulfides
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Gastrointestinal Stromal Tumors
×
Disulfides
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts